Dengue Literature Review

Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis

6 min read

Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis

Full citation: Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Experimental Biology and Medicine (Maywood), 236(5), 515–523 (2011).

Raw file: [[raw/lin2011.pdf]]

Summary

This minireview from the Lin/Lei group at National Cheng Kung University (NCKU), Taiwan, extends their earlier work (summarised in Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection) by providing a more molecularly detailed account of how dengue virus exploits molecular mimicry to cause immune-mediated pathology. The paper situates dengue within the broader field of virus-induced autoimmunity — presenting a systematic table of viruses and their associated autoimmune diseases — before narrowing to the specific NS1 and anti-prM mimicry mechanisms that cause haemorrhagic manifestations in DHF/DSS.

The key advance over Lin2006 is the identification of specific molecular targets: NS1 cross-reacts with PDI (protein disulfide isomerase), vimentin, ATP synthase β-chain, and HSP60 on platelets and endothelial cells. The C-terminal region of NS1 (aa 311–352) is identified as responsible for the platelet and endothelial cross-reactivity; deletion of this domain abolishes both platelet aggregation inhibition and endothelial dysfunction. Anti-prM antibodies are shown to cross-react with HSP60. The paper also catalogues sequence homology between 12 dengue protein regions and coagulatory factors, and identifies a six-amino-acid WGNGCG motif on the E protein (aa 101–106) that shares homology with coagulation factors XI, X, IX, VII, II (thrombin), plasminogen, and tPA. Importantly, this motif is conserved across related flaviviruses (JEV, WNV, YFV, TBE, OHFV) but absent in HCV — consistent with the clinical observation that HCV infection rarely causes haemorrhage.

The review also notes a clinically distinctive feature of dengue autoimmunity: unlike most virus-associated autoimmune diseases (which manifest weeks to months post-infection), dengue autoimmune manifestations occur during the acute phase of infection itself.

Study Design

  • Type: Minireview (narrative), synthesising experimental work from the NCKU group plus broader literature on virus-induced autoimmunity
  • Sample size: N/A (review); underlying studies used patient sera, cell lines (HUVEC, BHK-21, A549), and platelet preparations
  • Setting: National Cheng Kung University Medical College, Tainan, Taiwan
  • Population: DHF/DSS and DF patient sera; in vitro cell line experiments; sequence homology analyses

Key Findings

Virus-induced autoimmunity — broader context (Table 1):

  • Coxsackievirus B: Type I diabetes mellitus, Sjögren’s syndrome, myocarditis
  • HCV: Mixed cryoglobulinemia
  • Rubella virus: Type I diabetes mellitus
  • EBV: SLE, multiple sclerosis, Sjögren’s syndrome, rheumatoid arthritis
  • HCMV: SLE, multiple sclerosis
  • HSV: Stromal keratitis
  • Parvovirus B19: SLE, rheumatoid arthritis

NS1 molecular targets:

  • Anti-NS1 Abs cross-react with PDI (protein disulfide isomerase), vimentin, ATP synthase β-chain, and HSP60 on platelet and endothelial cell surfaces
  • NS1 C-terminal region (aa 311–352) is responsible for cross-reactivity: deletion of this domain abolishes anti-NS1-mediated platelet aggregation inhibition and endothelial cell dysfunction
  • Anti-NS1 scFv antibody (single-chain variable fragment) prolongs thrombin time in vitro — direct functional evidence for coagulation interference
  • Anti-NS1 inhibits platelet aggregation via PDI binding and inhibition

Anti-prM cross-reactivity:

  • Anti-prM antibodies cross-react with HSP60 on BHK-21 and A549 cell surfaces
  • Mechanism parallels anti-NS1 molecular mimicry; prM is a structural dengue protein distinct from the non-structural NS1

Coagulation factor homology (Table 2):

  • 12 dengue protein sequence regions share homology with human coagulatory factors
  • E protein aa 101–106 (WGNGCG motif) shares homology with factors XI, X, IX, VII, II (thrombin), plasminogen, and tPA
  • Anti-E protein Abs bind human plasminogen and inhibit plasmin activity — direct anti-fibrinolytic mechanism
  • This motif is conserved in JEV, WNV, YFV, TBE, and OHFV (flaviviruses associated with haemorrhage) but absent in HCV (which does not typically cause haemorrhagic disease)

Temporal specificity of dengue autoimmunity:

  • Dengue-associated autoimmunity uniquely manifests during the acute infection phase, in contrast to most other virus-induced autoimmune diseases (e.g., EBV-associated SLE, C. jejuni-associated GBS), which appear weeks to months after clearance of the pathogen
  • This temporal pattern suggests anti-NS1 cross-reactive Abs arise simultaneously with the anti-viral response and cause pathology while viraemia is still present

Post-dengue autoimmune syndrome:

  • References Garcia2009 (cited as Garcia G et al. Int J Infect Dis 2011;15:e38–43) for evidence of post-dengue autoimmune syndrome with persistent ANA, elevated IC, and prolonged symptoms at 2-year follow-up

Methods Used

  • Sequence homology analysis (dengue proteins vs. coagulation factors; flavivirus cross-species comparison)
  • Anti-NS1 scFv generation
  • Thrombin time prolongation assay
  • Platelet aggregation inhibition assays
  • Co-immunoprecipitation and Western blot (NS1 vs. PDI/vimentin/HSP60/ATP-synthase β)
  • Cell surface staining (BHK-21, A549, HUVEC)
  • C-terminal NS1 deletion constructs

Entities Mentioned

  • NS1 Protein (central subject; autoantigenic epitopes, C-terminal domain, molecular targets)
  • Aedes aegypti (vector; background)

Concepts Addressed

Relevance & Notes

Lin2011 provides the molecular resolution that Lin2006 lacked: it names the specific host proteins that anti-NS1 cross-reacts with (PDI, vimentin, ATP synthase β, HSP60) and maps the responsible NS1 domain to the C-terminal aa 311–352 region. This level of specificity is essential for understanding both the mechanism of thrombocytopenia (PDI-mediated platelet aggregation inhibition) and the vaccine design implication from Lin2006 (C-terminal epitopes must be excluded from NS1-based vaccines to avoid autoimmune cross-reactivity).

The flavivirus WGNGCG motif comparison (Fig. 2) is a striking piece of evidence: the presence/absence of this coagulation-factor-homologous motif tracks with the haemorrhagic vs. non-haemorrhagic phenotype of flaviviruses, providing independent molecular support for the anti-E protein coagulation interference mechanism alongside the NS1 platelet/endothelial mechanism.

The acute-phase timing of dengue autoimmunity is mechanistically important: it is consistent with rapid autoantibody production during primary viraemia, driven by NS1 antigen stimulation, rather than the slower processes of epitope spreading or post-infectious molecular mimicry characteristic of other viral autoimmune diseases.

Lin2011 cross-references Garcia2009 - Long-term Clinical Symptoms Post-Dengue for post-dengue autoimmune syndrome (the same cohort), confirming that the NCKU group was aware of the Cuban post-dengue ANA data, though they do not specifically address the 2-year ANA persistence question.

Questions Raised

  1. Which of the four NS1 molecular targets (PDI, vimentin, ATP synthase β-chain, HSP60) is the dominant driver of thrombocytopenia vs. endothelial dysfunction — and does the clinical severity of DHF correlate with differential targeting?
  2. Does the C-terminal NS1 deletion that abolishes cross-reactivity in vitro also abrogate anti-viral protection — i.e., is there an unavoidable trade-off between immunogenicity and autoimmune risk in NS1-based vaccines?
  3. Does anti-prM (cross-reacting with HSP60) contribute independently to endothelial damage, or does its contribution overlap with anti-NS1 via shared HSP60 targeting?
  4. If the WGNGCG motif is the key coagulation-homologous sequence, do dengue-endemic populations develop tolerance to anti-E antibody activity on plasminogen — and might this differ between primary and secondary infection?
  5. Given that dengue autoimmunity occurs acutely (unlike most virus-induced autoimmunity), is there a window for clinical intervention to interrupt anti-NS1 autoantibody production before the nadir of thrombocytopenia?

Graph View

Backlinks